These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38126207)

  • 41. Comment on: Reclassification into very-high cardiovascular risk in psoriatic arthritis as well as axial spondyloarthritis.
    Martínez-Vidal MP; Lorenzo-Martín JA; Andrés M; Jovaní V; Santos-Ramírez C; Romera-López C; Fernández-Carballido C; Queiró-Silva R
    Clin Exp Rheumatol; 2020; 38(6):1267. PubMed ID: 32573424
    [No Abstract]   [Full Text] [Related]  

  • 42. Toxicological considerations in the treatment of axial spondylo-arthritis.
    Marino F; D'Angelo S; Masala IF; Gerratana E; Nucera V; La Corte L; Giallanza M; Sarzi-Puttini P; Atzeni F
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):663-672. PubMed ID: 32552128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reply to: Comment on: Reclassification into very-high cardiovascular risk in psoriatic arthritis as well as axial spondyloarthritis.
    Ferraz-Amaro I; Rueda-Gotor J; González-Gay MA
    Clin Exp Rheumatol; 2020; 38(6):1268. PubMed ID: 32573427
    [No Abstract]   [Full Text] [Related]  

  • 44. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
    Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endothelial dysfunction and increased carotid intima-media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors.
    Ben Tekaya A; Boukriba S; Fendri A; Rouached L; Saidane O; Bouden S; Tekaya R; Ben Salem K; Mahmoud I; Habiba M; Abdelmoula L
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35793876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis.
    Wendling D; Lukas C; Prati C; Claudepierre P; Gossec L; Goupille P; Hudry C; Miceli-Richard C; Molto A; Pham T; Saraux A; Dougados M
    Joint Bone Spine; 2018 May; 85(3):275-284. PubMed ID: 29407043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological therapy of spondyloarthritis.
    Palazzi C; D'Angelo S; Gilio M; Leccese P; Padula A; Olivieri I
    Expert Opin Pharmacother; 2015; 16(10):1495-504. PubMed ID: 26073668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New evidence on the management of spondyloarthritis.
    Sieper J; Poddubnyy D
    Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older Patients.
    Felten R; Toussirot E
    Drugs Aging; 2023 Dec; 40(12):1101-1112. PubMed ID: 37902947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis.
    Ono K; Kishimoto M; Deshpande GA; Fukui S; Kawaai S; Sawada H; Matsuura M; Rodriguez VR; Proft F; Tada K; Tamura N; Taniguchi Y; Hirata A; Kameda H; Tsuji S; Kaneko Y; Dobashi H; Okano T; Haji Y; Morita A; Okada M; Komagata Y; Medina CL; Molto A; Dougados M; Hisamatsu T; Tomita T; Kaname S
    Rheumatol Int; 2022 Oct; 42(10):1751-1766. PubMed ID: 35532790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis.
    Mitulescu TC; Popescu C; Naie A; Predeţeanu D; Popescu V; Alexandrescu C; Voinea LM
    J Med Life; 2015; 8(3):319-25. PubMed ID: 26351533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Axial spondyloarthritis: thoughts about nomenclature and treatment targets.
    Braun J
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S132-5. PubMed ID: 23079005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project.
    López-Medina C; Jiménez-Gómez Y; Moltó A; Schiotis RE; Marzo-Ortega H; van Gaalen FA; Ozgocmen S; Dougados M; Calvo-Gutiérrez J; Castro-Villegas MC; Collantes-Estévez E; Font-Ugalde P;
    Joint Bone Spine; 2018 Jul; 85(4):447-453. PubMed ID: 28754402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis.
    Machado PM; Raychaudhuri SP
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):711-28. PubMed ID: 25488780
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
    Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
    J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports.
    Nagayasu A; Nawata M; Saito K; Tanaka Y
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):176-180. PubMed ID: 33086996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study.
    Sieper J; Srinivasan S; Zamani O; Mielants H; Choquette D; Pavelka K; Loft AG; Géher P; Danda D; Reitblat T; Cantini F; Ancuta C; Erdes S; Raffayová H; Keat A; Gaston JS; Praprotnik S; Vastesaeger N
    Ann Rheum Dis; 2013 Oct; 72(10):1621-7. PubMed ID: 23065731
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study.
    Couderc M; Pereira B; Molto A; Tiple A; Soubrier M; Dougados M
    J Rheumatol; 2018 Jun; 45(6):795-801. PubMed ID: 29657148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.